E

Elliquence

Manufactures minimally invasive neurosurgery devices

Overview

Elliquence develops and sells medical devices for minimally invasive spine, neurosurgery, orthopedic, and pain-management procedures. Its core tool is the Surgi-Max energy source using 4.0 MHz radiowave energy to cut, coagulate, and ablate tissue with minimal thermal damage, paired with capital equipment (Surgi-Max Plus) and disposable instruments like Disc-FX and Trigger-Flex. The company also offers HD endoscopes, drills, and ultrasonic bone-cutting devices and runs surgical trainings to promote adoption. By combining a long heritage with an end-to-end equipment and instrument platform and education, Elliquence aims to improve patient outcomes and expand global use of its techniques.

Work here?Claim your company

About Elliquence

Simplify's Rating
Why Elliquence is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & ManufacturingHealthcare

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Hempstead, NY

Founded

2008

Get referred to Elliquence

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • elliquence highlighted ISASS EndoSpine Academy 2026 on March 12, 2026.
  • Pfost’s October 2026 appointment targets broader U.S. and global market expansion.
  • The company’s disposable instruments create recurring revenue after capital equipment placements.

What critics are saying

  • Pfost’s October 2026 CEO change signals prior commercial underperformance and leadership reset.
  • Endoscopic spine adoption depends on surgeon training, delaying revenue until 2027 or later.
  • Medtronic, J&J, and NuVasive can outspend elliquence on distribution and clinical evidence.

What makes Elliquence unique

  • Surgi-Max’s 4.0 MHz radiowave platform targets soft tissue with low thermal damage.
  • elliquence spans endoscopic spine, neurosurgery, orthopedics, and pain management from one platform.
  • Bill Pfost joined October 8, 2026, bringing thirty years of spine commercialization experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours

Company News

PR Newswire
Oct 8th, 2026
elliquence names spine industry veteran Bill Pfost Chief Executive Officer.

elliquence names spine industry veteran Bill Pfost Chief Executive Officer. Elliquence Oct 08, 2026, 09:00 ET Appointment of Bill Pfost brings more than three decades of spine industry experience to support the company's continued growth and broader adoption of minimally invasive endoscopic spine solutions. BALDWIN, N.Y., Oct. 8, 2026 /PRNewswire-PRWeb/ - elliquence, LLC, a global leader in minimally invasive surgical technologies, today announced the appointment of Bill Pfost as Chief Executive Officer. A seasoned medical device executive with more than 30 years of experience in the spine industry, he will lead elliquence as the company continues to expand its presence in the U.S. and global markets and advance the adoption of minimally invasive endoscopic approaches to spine care. Pfost brings extensive commercial and executive leadership experience to elliquence, with a career spanning the development, commercialization and distribution of some of the spine industry's most recognized technologies. Most recently, he served as Chief Revenue Officer of Companion Spine, driving the company's vision as a leader in posterior dynamic stabilization. His previous leadership roles include executive positions at Zimmer Spine, Paradigm Spine, and American Medical Concepts. "Bill brings a rare combination of deep spine industry experience, commercial leadership and an understanding of how innovative technologies gain acceptance among physicians and patients," said Daniel Hui, member of the elliquence Board of Directors. "As elliquence works to broaden awareness and adoption of endoscopic approaches to spine care, his industry knowledge, relationships and perspective on the evolving treatment landscape will be invaluable in guiding the company's next stage of growth." The appointment comes as elliquence continues to build awareness of minimally invasive endoscopic techniques as an important option across a range of spine conditions and procedures. By enabling physicians to access and treat targeted anatomy with minimal disruption to surrounding healthy tissue, endoscopic interventions may offer appropriately selected patients reduced recovery times and the potential for same-day outpatient treatment. This approach reflects elliquence's longstanding philosophy that, when clinically appropriate, less intervention can deliver meaningful benefits for both physicians and patients. "Throughout my career, I've seen how advances in minimally invasive techniques can fundamentally change the way physicians approach patient care," said Pfost. "I believe that elliquence is well-positioned to evolve as a leader in the advancement of endoscopic procedures. elliquence has spent decades developing the technologies, clinical relationships and expertise to help advance this approach, and I'm excited to build on that foundation, broaden its adoption and lead the company into its next phase of growth." Pfost began his career at U.S. Surgical Corporation, where he played a role in driving adoption of laparoscopic cholecystectomy as minimally invasive surgical techniques were transforming general surgery. Over the ensuing three decades, he has held senior sales, marketing and executive leadership positions across the medical device and spine industries and has been involved in the development and distribution of less invasive and interventional technologies. As CEO, Pfost will provide strategic leadership across elliquence's operations, commercial organization and continued market development, with an emphasis on expanding the understanding of endoscopic spine procedures among physicians and patients and supporting the company's long-term growth. About elliquence elliquence, LLC is a leading medical device company based in New York, specializing in advanced minimally invasive surgical technologies. With over 50 years of innovation, elliquence is recognized globally for its Surgi-Max Ultra radiofrequency platform alongside its Trigger-Flex bipolar systems, which provides surgeons with unparalleled precision in soft tissue management and preservation. The company's mission is to partner with the medical community to develop high-quality, cost-effective solutions that enhance patient outcomes while reducing procedural risks and recovery times. elliquence's cutting-edge technologies are widely used in endoscopic spine surgery, orthopedics, neurosurgery, and pain management. Known for pushing the boundaries of surgical innovation, elliquence continues to lead the charge in improving the efficiency and effectiveness of minimally invasive procedures. Media Contact Scott Truelson, Elliquence, 1 516.277.9016, [email protected], Elliquence.com SOURCE Elliquence

Recently Posted Jobs

Sign up to get curated job recommendations

Elliquence is Hiring for 4 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs